Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

650
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
650
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

925
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
925
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

2.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
2.8K
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

891
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
891

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cholesterol-lowering therapy from childhood/adolescence and long-term outcomes in familial hypercholesterolaemia: the SAFEHEART study.

European heart journal·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same author

Ibero-American position statement on therapeutic recommendations for the preventive management of cardiovascular complications in latin-American patients with type 2 diabetes mellitus: consensus of the prevention council of the inter-American society of cardiology (SIAC-PREVENT).

Diabetology & metabolic syndrome·2026
Same author

Construction and characterization of the first Arcobacter butzleri - Escherichia coli shuttle vector.

Archives of microbiology·2026
Same author

Functional analysis from ex-vivo characterization of LDLR exon 13-15 duplication associated to familial hypercholesterolemia.

Frontiers in endocrinology·2026

Related Experiment Video

Updated: Apr 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

[New lipid lowering agents].

Ada Cuevas, María Magdalena Farías, Rodrigo Alonso

    Revista Medica De Chile
    |November 8, 2014
    PubMed
    Summary
    This summary is machine-generated.

    New therapies effectively lower LDL-cholesterol in severe hypercholesterolemia cases where statins are insufficient. These novel agents show promise, but long-term studies are needed to confirm their safety and cardiovascular benefits.

    More Related Videos

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.3K
    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
    08:18

    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

    Published on: July 27, 2022

    1.7K

    Related Experiment Videos

    Last Updated: Apr 21, 2026

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    15.2K
    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
    08:45

    LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

    Published on: November 17, 2018

    14.3K
    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
    08:18

    Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

    Published on: July 27, 2022

    1.7K

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology
    • Genetics

    Background:

    • Statins are primary treatments for hypercholesterolemia, reducing cardiovascular risks.
    • Severe hypercholesterolemia (e.g., familial hypercholesterolemia) or statin intolerance can limit statin efficacy.
    • Novel lipid-lowering agents offer alternative treatment strategies.

    Purpose of the Study:

    • To review the effectiveness and safety of new lipid-lowering agents for severe hypercholesterolemia.
    • To assess these agents in patients with homozygous or heterozygous familial hypercholesterolemia.
    • To evaluate their role in statin-intolerant populations.

    Main Methods:

    • Review of studies on novel lipid-lowering therapies.
    • Inclusion of agents like Lomitapide, Mipomersen, and PCSK9 inhibitors.
    • Analysis of short-term safety and efficacy data.

    Main Results:

    • New therapies demonstrate significant LDL-cholesterol reduction in severe hypercholesterolemia.
    • Short-term studies indicate an acceptable safety profile, particularly in homozygous familial hypercholesterolemia.
    • Some agents show potential for statin-intolerant patients.

    Conclusions:

    • Novel agents are effective for managing severe hypercholesterolemia when statins are insufficient.
    • Further long-term studies are essential to fully ascertain the safety, efficacy, and cardiovascular impact of these new therapies.